Published in J Med Chem on October 06, 2005
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol (2008) 1.25
Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One (2009) 1.14
Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn (2006) 1.05
Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics (2010) 0.95
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol (2011) 0.91
Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms. Immunol Allergy Clin North Am (2014) 0.86
Ellipticine derivative induces potent cytostatic effect in acute myeloid leukaemia cells. Invest New Drugs (2014) 0.81
7-formyl-10-methylisoellipticine, a novel ellipticine derivative, induces mitochondrial reactive oxygen species (ROS) and shows anti-leukaemic activity in mice. Invest New Drugs (2015) 0.75
Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol (2009) 2.94
DNAM-1 and PVR regulate monocyte migration through endothelial junctions. J Exp Med (2004) 1.96
Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis. J Natl Cancer Inst (2006) 1.80
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One (2009) 1.55
Prominent role of the Ig-like V domain in trans-interactions of nectins. Nectin3 and nectin 4 bind to the predicted C-C'-C"-D beta-strands of the nectin1 V domain. J Biol Chem (2002) 1.54
Small fibre impairment predicts neuropathic pain in Guillain-Barré syndrome. Pain (2010) 1.49
Mast cell leukemia. Blood (2012) 1.42
Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem (2005) 1.34
The Escherichia coli RecQ helicase functions as a monomer. J Biol Chem (2003) 1.31
Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. Mol Cancer Res (2008) 1.31
Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer (2007) 1.30
The tumor suppressor activity of SOCS-1. Oncogene (2002) 1.29
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene (2003) 1.23
Signal transduction by several KIT juxtamembrane domain mutations. Oncogene (2003) 1.20
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med (2005) 1.18
In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood (2012) 1.10
Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem (2004) 1.08
Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol Immunol (2007) 1.07
Case-control cohort study of patients' perceptions of disability in mastocytosis. PLoS One (2008) 1.07
Effective cross sections for production of single-strand breaks in plasmid DNA by 0.1 to 4.7 eV electrons. Radiat Res (2006) 1.07
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One (2010) 1.05
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther (2009) 1.05
Post-translational modifications of histones H3 and H4 associated with the histone methyltransferases Suv39h1 and G9a. Genome Biol (2007) 1.05
Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol Pharmacol (2004) 1.03
Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell (2005) 1.01
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol (2010) 1.01
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood (2006) 0.99
Suppressor of cytokine signaling 6 associates with KIT and regulates KIT receptor signaling. J Biol Chem (2004) 0.99
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One (2008) 0.98
The E3 ubiquitin ligase HOIL-1 induces the polyubiquitination and degradation of SOCS6 associated proteins. FEBS Lett (2006) 0.98
The actin cytoskeleton-associated protein zyxin acts as a tumor suppressor in Ewing tumor cells. Exp Cell Res (2004) 0.97
Flavonoid profiling among wild type and related GM wheat varieties. Plant Mol Biol (2007) 0.97
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol (2012) 0.97
Probing of HIV-1 integrase/DNA interactions using novel analogs of viral DNA. J Biol Chem (2006) 0.97
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther (2011) 0.96
Critical involvement of the ATM-dependent DNA damage response in the apoptotic demise of HIV-1-elicited syncytia. PLoS One (2008) 0.95
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor. Eur J Haematol (2012) 0.95
Allosteric communication across the native and mutated KIT receptor tyrosine kinase. PLoS Comput Biol (2012) 0.94
Protein kinase D1 stimulates proliferation and enhances tumorigenesis of MCF-7 human breast cancer cells through a MEK/ERK-dependent signaling pathway. Exp Cell Res (2012) 0.94
In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients. Proc Natl Acad Sci U S A (2006) 0.94
Oncogenic tyrosine kinase of malignant hemopathy targets the centrosome. Cancer Res (2005) 0.93
The tyrosine kinase FES is an essential effector of KITD816V proliferation signal. Blood (2007) 0.93
SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. Haematologica (2014) 0.93
The aberrant localization of oncogenic kit tyrosine kinase receptor mutants is reversed on specific inhibitory treatment. Mol Cancer Res (2009) 0.92
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol (2011) 0.91
Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflamm Bowel Dis (2010) 0.90
Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J Biol Chem (2010) 0.88
PICK-1: a scaffold protein that interacts with Nectins and JAMs at cell junctions. FEBS Lett (2005) 0.87
Kit signaling inhibits the sphingomyelin-ceramide pathway through PLC gamma 1: implication in stem cell factor radioprotective effect. Blood (2002) 0.87
Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor. Blood (2011) 0.86
Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. Oncol Rep (2006) 0.86
Desmoid-type fibromatosis. J Neurosurg (2007) 0.85
Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket. PLoS One (2013) 0.85
Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature. J Clin Oncol (2012) 0.85
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. Am J Vet Res (2010) 0.83
Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling. Eur J Med Chem (2011) 0.83
Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol (2013) 0.83
Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines. J Med Chem (2002) 0.82
Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis. J Pediatr (2012) 0.82
Chemical modification of coumarin dimer and HIV-1 integrase inhibitory activity. Chem Pharm Bull (Tokyo) (2002) 0.82
NACA is a positive regulator of human erythroid-cell differentiation. J Cell Sci (2005) 0.82
Functional analysis of novel sonic hedgehog gene mutations identified in basal cell carcinomas from xeroderma pigmentosum patients. Cancer Res (2004) 0.81
[Cost of hospital-based management of acute myeloid leukemia: from analytical to procedure-based tarification]. Bull Cancer (2006) 0.81
Neuroprotective effect of masitinib in rats with postischemic stroke. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.80
Differential effects of two growth inhibitory K vitamin analogs on cell cycle regulating proteins in human hepatoma cells. Life Sci (2003) 0.80
Hamming distance geometry of a protein conformational space: application to the clustering of a 4-ns molecular dynamics trajectory of the HIV-1 integrase catalytic core. Proteins (2002) 0.80
Nectin-3 (CD113) interacts with Nectin-2 (CD112) to promote lymphocyte transendothelial migration. PLoS One (2013) 0.78
Pyridocoumarin, aristolactam and aporphine alkaloids from the Australian rainforest plant Goniothalamus australis. Phytochemistry (2012) 0.78
Leukocyte telomere length in mastocytosis: correlations with depression and perceived stress. Brain Behav Immun (2013) 0.78
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. Br J Haematol (2013) 0.78
Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial. Vet Dermatol (2011) 0.77
Assessment of cellular actin dynamics by measurement of fluorescence anisotropy. Anal Biochem (2007) 0.77
Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients. J Cell Mol Med (2014) 0.77
EWS-FLI1 inhibits TNFalpha-induced NFkappaB-dependent transcription in Ewing sarcoma cells. Biochem Biophys Res Commun (2010) 0.77
FES kinase participates in KIT-ligand induced chemotaxis. Biochem Biophys Res Commun (2010) 0.77
Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity. Bioorg Med Chem Lett (2004) 0.76
Cell-penetrating peptides with intracellular actin-remodeling activity in malignant fibroblasts. J Biol Chem (2009) 0.76
Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP-2 and TIMP-3. Cancer Gene Ther (2003) 0.76
Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications. Clin Lymphoma Myeloma Leuk (2012) 0.76
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma. JAMA Dermatol (2014) 0.76
Presence of divalent cation is not mandatory for the formation of intramolecular purine-motif triplex containing human c-jun protooncogene target. Biochemistry (2011) 0.75
Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients. Medicine (Baltimore) (2016) 0.75
Comparative molecular surface analysis (CoMSA) for virtual combinatorial library screening of styrylquinoline HIV-1 blocking agents. Comb Chem High Throughput Screen (2006) 0.75
Ab initio determination of the flexibility of 2'-aminoribonucleosides and 2'-aminoarabinonucleosides inserted in duplexes. J Comput Chem (2008) 0.75
[Tyrosine kinase inhibitors (TKI), a concept and acronym of the future]. Med Sci (Paris) (2003) 0.75
Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors. Bioorg Med Chem Lett (2005) 0.75
[3/4 Level II and III analgesics (part 1)]. Soins (2006) 0.75
Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study. Maturitas (2009) 0.75
[4/4 Level II and III analgesics (part 2)]. Soins (2006) 0.75